Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidino
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... Market Monitor : Global Chiral Separation Columns Market" ... chromatography is a technique involving two enantiomers of the ... consisting of a single enantiomer, thus possessing different elution ... such as cellulose. The chiral separation chromatography ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources ... the United States , 54 ... GlaxoSmithKline,s BRAF inhibitor Tafinlar for BRAF -mutation-positive ... who have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among ... percentage (42 percent and 43 percent, respectively) expects ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2Micro Market Monitor: Global Chiral Separation Columns Market 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2
... The award recognizes outstanding journalism demonstrating the ... discoveries and scientific,breakthroughs., WASHINGTON, June 19 ... announces the winners of the 7th Annual,Michael ... in honor of FBR,s,Chairman and 2008 Congressional ...
... Kendle (Nasdaq: KNDL ), a,leading global full-service ... its experts will present at the upcoming Drug,Information ... scheduled,for June 22-26, 2008, at the Boston Convention ... speak on key topics in the clinical,development industry, ...
Cached Medicine Technology:The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 3
(Date:9/18/2014)... jacket is a hip- or waist-length garment for the ... in the front or slightly on the side. A ... a coat, which is outerwear. Some jackets are fashionable, ... well-known clothing manufacturer and retailer, has delightedly released its ... are offered at extremely low prices? , The ...
(Date:9/18/2014)... Older people become more physically vulnerable during bereavement, new ... hormones during bereavement changes with age, British researchers say. ... more likely to have weakened immune systems and develop ... and months after loss, we can suffer from reduced ... white blood cell and as such are essential at ...
(Date:9/18/2014)... Limited spots remain at Becker's Healthcare's upcoming ... are still available for Becker's ASC 21st Annual Meeting ... 23-25, 2014 at the Swissotel Chicago. , Only 10 ... Strategy Roundtable on November 4, 2014 at the Ritz ... Hospital Review Chief Executive Officer Strategy Roundtable on November ...
(Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... can quickly alter the way brain cells communicate with one ... Sept. 18 in Current Biology , are a step ... Experts said the hope is to eventually be able to ... a drug -- and which people would fare better with ...
Breaking Medicine News(10 mins):Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
... States Senate Committee on Small Business and Entrepreneurship ... J. Snowe, R-Maine, today convened a roundtable to ... small businesses. Participants at the roundtable, entitled "Healthcare ... of Small Businesses," included U.S. Sen. Ron Wyden, ...
... -- Skyrocketing prescription drug prices are stinging Illinoisans over the ... the basics, like food and utilities, in order to afford needed ... drugs see record price increases, the majority of the state,s 50 ... medications in the coming year. , , "No ...
... "Keratosis Pilaris," "Keratosis Pilaris." Hmm, sounds weird, doesn,t it? ... to the American Academy of Dermatology nags 40 percent of ... family of moisturizers is launching www.littleredbumps.com , ... associated with Keratosis Pilaris also known as KP. , ...
... OAKLAND, Calif., July 9 Members of SEIU UHW ... outside the Oakland Federal Building, 1301 Clay Street, to release newly ... former top union officials were advised by their attorney that some ... and then followed their lawyer,s advice on how to cover them ...
... can cause menstrual woes, infertility, researchers note , THURSDAY, ... bring some relief to the one in 10 women ... disease called polycystic ovarian syndrome (PCOS). , ... hormones -- including testosterone -- and often develop ovarian ...
... chest pain patients in the emergency department, instead of the ... length of stay and hospital charges, according to a study ... WA. The SOC workup, which is timely and expensive, consists ... stress testing. , , Fifty patients were included in ...
Cached Medicine News:Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3Health News:High Rx Costs Hammering Illinois' 50+ Population 2Health News:Video: What Are Those Little Red Bumps? 2Health News:Video: What Are Those Little Red Bumps? 3Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Acupuncture, Exercise May Ease Polycystic Ovarian Syndrome 2
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... cover the range from 2ul to 5000ul. ... lock design prevents inadvertent volume change. Novel ... Whole pipette is autoclavable at 121C(250F). To ... Suitable for one-handed operation. Auto or ...
... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
Medicine Products: